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Abstract Lenalidomide has particular activity in patients
with transfusion-dependent del(5q) myelodysplastic syn-
dromes (MDS), but mechanistic information is limited
regarding the relationship between erythroid and cytoge-
netic responses. We reviewed medical records from three
distinct subgroups of del(5q) MDS patients who had
unexpected effects with lenalidomide treatment: 1. two
patients with complex karyotypes who achieved both
cytogenetic remissions and transfusion independence; 2.
two patients with 5q- syndrome who took lenalidomide for
less than 12 weeks but remained transfusion independent
for 15+ months still displaying del(5q) metaphases after 6
and 12 months; and 3. one patient who was a non-
responder on lenalidomide during treatment but became
transfusion independent for 13+ months after discontinua-
tion. All but the latter patient in this series had reduction of
affected metaphases, suggesting that erythroid responses
might be mediated by result from partial or complete
suppression of the malignant clone, either directly or
indirectly through modulation of the bone marrow micro-
environment. These clinical observations illustrate the
heterogeneity of del(5q)MDS pathogenesis and the diversi-
ty of lenalidomide responses within this patient subset.
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Introduction
Myelodysplastic syndromes (MDS) with chromosomal
deletion of 5q [del(5q) MDS] are heterogeneous diseases
[3, 5]. Apart from the 5q- syndrome [7, 16], patients with
del(5q) MDS may present with one additional chromosom-
al abnormality, with multiple additional chromosomal
abnormalities leading to a complex karyotype, or with an
increase of bone marrow and/or peripheral blasts irrespec-
tive of chromosomal complexity. These distinct disease
subgroups have dramatically different prognostic features
[3, 5, 6, 12].
Lenalidomide is a thalidomide analog with a distinct
clinical profile that has demonstrated erythroid
responses leading to RBC transfusion independence,
particularly in del(5q) MDS [10, 11]a n di ns o m e
patients with Low or Int-1 MDS lacking the del(5q)
chromosomal abnormality [14]. Although the exact
mechanism of action has not been defined, lenalidomide
is known to have multiple biological activities including
anti-angiogenesis, immunomodulation, anti-cytokine,
and direct toxic effects on malignant bone marrow cells
[1, 4].
We experienced unexpected effects of lenalidomide in
del(5q) MDS patients that are suggestive of the mode of
action in this patient subgroup and may have implications
for future use of the substance in this patient population. To
our knowledge, these types of responses to lenalidomide
have not been previously described.
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Between November 2003 and May 2006, 43 patients with
del(5q) MDS with or without additional chromosomal
abnormalities were treated with lenalidomide at St.
Johannes Hospital, Medizinsche Klinik II, Duisburg,
Germany. As of December 27, 2005, lenalidomide has
been approved for clinical use in the United States, but not
in Europe. These patients received lenalidomide as partic-
ipants of clinical trials or through an expanded access
program. Of the cases reported in this paper, only one
patient took part in a lenalidomide clinical trial, and that
patient was a non-responder. Patients were informed of
inclusion of their information in the present report and
consent was given.
Results and discussion
Patients with complex karyotypes
Patient 1
A 59-year-old man diagnosed in October 2005 with
International Prognostic Scoring System (IPSS) [9] Int-2
risk MDS, >5% bone marrow blasts (RAEB-I) [2, 17], one
cytopenia, and complex karyotype: 44, XY, del (5)
(q13q33), -7, -15, -18, -19, -19, +mar (15)/46, XY(7) was
transfusion-dependent and received two units of packed
RBC every 2 to 3 weeks since diagnosis. He had a previous
history of two myocardial infarctions, insulin-dependent
diabetes mellitus, arterial hypertension, and deep venous
thrombosis. Treatment with lenalidomide (10 mg p.o., once
daily) commenced in December 2005 and this patient has
remained on treatment as of May 2006. He experienced
grade 1 neutropenia and grade 2 thrombocytopenia, which
required no treatment. The time to transfusion indepen-
dence was immediate; no further transfusions were required
after the initiation of lenalidomide treatment. Hemoglobin
was>13g/dlafter8weeks,althoughthetimetonormalization
of hemoglobin (normal level at local laboratory=14 g/dl) has
not been reached. Repeat cytogenetic analyses conducted in
January and March 2006 showed consistent reductions in the
number of abnormal metaphases (Table 1).
Patient 2
A 78-year-old woman with IPSS Int-1 MDS [no blasts, one
cytopenia, complex karyotype: 46, XX, der(1)t(1:2)(p13;?),
der(2)t(1;2)(p13;q31)del(2)(p23), del(5)(q15q31)(19)/46,
XX (1)], who was diagnosed in March 2004, had an RBC
transfusion requirement of two packed RBC every 8 weeks.
This lady’s case report has been published in an earlier
issue of this journal, but with a shorter follow-up [6]. She
had a previous medical history of grade 1 renal insufficien-
cy. Treatment with lenalidomide (10 mg p.o. once daily)
commenced in July 2004. The dosage was reduced to 5 mg
p.o. once daily from November 2004 to November 2005,
and was subsequently reduced to 5 mg p.o. every other day
from November 2005 to present. The actual treatment
duration was 22 months.
Adverse events included grade 2 neutropenia, grade 2
thrombocytopenia, and grade 3 scalp itching. Whereas
neutropenia and thrombocytopenia required no additional
medication, scalp itching was treated with antihistamines
and low doses of prednisone (10 mg) for 2 weeks.
Transfusion independence was reached after 1 month and
normalization of hemoglobin was reached after 4 months of
treatment. Repeat cytogenetic analyses showed complete
cytogenetic remission with no evidence of 5(q31) deletion
in December 2004 (4 months after start of treatment), in
June 2005 and in January 2006 (Table 1). This del(5q)
patient with a complex karyotype achieved both durable
complete cytogenetic remission and long-term RBC trans-
fusion independence.
Table 1 Sequential bone marrow cytogenetic analyses
Patient
number
Analysis
date
Karyotype
1 10/2005 44, XY, del(5)(q13q33), −7, −15, −18, −19,
−19, +3mar [15]/46, XY [7]
1/2006 44, XY, del(5)(q13q33), −7, −15, add(18)
(p11), −19, add(19)(q12)[8]/46, XY [7]
3/2006 45, XY, del(5)(q13q33), −7, der(12;14)
(q10;10), −14, −15, add(18)(p11), −19,
add(19)(q12), +3mar [3]/46; XY [17]
2 3/2004 46, XX, der(1)t(1;2)(p13;?), der(2)t(1;2)
(p13;q31)del(2)(p23), del(5)(q15q31)
[19]/ 46, XX [1]
12/2004
(FISH)
No evidence of 5q31 deletion
6/2005
(FISH)
No evidence of 5q31 deletion
1/2006 No evidence of 5q31 deletion
3 2/2004 46, XX, del(5)(q13q33) [20]
5/2005 46, XX, del(5)(q13q33) [12]/ 46, XX [13]
4 5/2004 46, XY, del(5)(q13q33) [20]
12/2005 46, XY, del(5)(q13q33) [13]/ 46, XY [8]
5 1/1996 46, XX, del(5)(q13q33) [15]
10/2002 No change, non-mosaic pattern of del(5q)
3/2003
12/2003
6/2004
11/2004
06/2006
(FISH) indicates that additional fluorescence in situ hybridization was
performed.
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interruption of medication
Patient 3
A 33-year-old woman was diagnosed in February 2004
with IPSS Low-risk MDS (no blasts, one cytopenia) and del
(5)(q13q33) as the sole karyotypic abnormality, disease
characteristics that are consistent with 5q- syndrome. She
had a transfusion requirement of two packed RBC units
every 3 to 4 weeks. Lenalidomide treatment was started in
November 2004, but therapy was interrupted after 28 days
for erythematous lesions of the skin and grade 4 neutrope-
nia. Transfusion independence was reached after 8 weeks
without further medication and normalization of hemoglo-
bin was achieved after 20 weeks. Grade 1 neutropenia
persisted. Repeat bone marrow cytogenetics in May 2005
showed a reduction in del(5q) metaphases (Table 1).
Although treatment was interrupted due to toxicity, this
patient continued to improve with respect to both erythroid
response and the number of del(5q) metaphases. This
patient remains transfusion independent at 21 months after
commencement of lenalidomide therapy and 20 months
after discontinuation of therapy.
Patient 4
A 49-year-old man with IPSS Low-risk MDS typical of 5q-
syndrome [no blasts, one cytopenia, isolated del(5)
(q13q33)] was diagnosed May 2004. He was transfusion-
dependent, requiring two packed RBC units every 2 weeks
before the start of lenalidomide therapy in November 2004.
However, treatment was stopped after 12 weeks (February
2005) because of grade 3 skin itching. Transfusion
independence had been reached after 8 weeks of treatment.
Normalization of hemoglobin was achieved after 16 weeks
and was ongoing at last visit (21 months) despite receiving
no additional treatment. Mild leukopenia has persisted. A
repeat karyotype analysis in December 2005 (13 months
after onset of therapy) showed a reduction in del(5q)
metaphases and no evidence of cytogenetic evolution
(Table 1). The lengthy duration of response in this patient
was notable and unexpected considering the relatively short
treatment period and the persistence of the del(5q) clone.
Patient with no response during treatment but transfusion
independence after discontinuation
Patient 5
A 58-year-old woman with no relevant previous history
was diagnosed January 1996 with IPSS Low-risk MDS (no
blasts, one cytopenia) with del(5)(q13q33) as the sole
karyotypic abnormality. She was transfusion-dependent,
receiving two packed RBC units every 4 weeks. Low-dose
cytarabine was given in December 1996, resulting in
10 months of transfusion independence, but was again
given in January 1998 without effect. All-trans-retinoic
acid was administered from July 2002 to January 2003
without improvement of transfusion burden. She subse-
quently received lenalidomide from January 2004 to
November 2004 without reduction in transfusions.
This prolonged treatment of more than 10 months was
administered in the hope of induction of a late response to
the drug. Her hemoglobin value at commencement of
lenalidomide therapy was 7.1 g/dl, and she needed two red
blood cell transfusions every 3 weeks to maintain these
levels throughout drug intake. However, 16 weeks after
lenalidomide discontinuation, transfusion independence
was achieved in this patient (March 2005) and without
additional measures. The response had been ongoing for
16 months, without normalization of hemoglobin (10.9 g/dl
at last visit in June 2006). Six repeat karyotype analyses
from Oct 2002 to June 2006 all showed the initial finding
of a non-mosaic pattern of del(5q) (Table 1).
Discussion
Clinical trials of lenalidomide have demonstrated cytoge-
netic and erythroid responses in patients with del(5q) MDS
[10, 11] that have not been achieved with other non-
cytotoxic agents [8]. The activity of lenalidomide in
patients with complex karyotypes including del(5q) repre-
sents a major advance, as those patients have an ominous
prognosis and are expected to transform rapidly to acute
myeloid leukemia [6]. Patient 1, who had Int-2 MDS with
del(5q) and a complex karyotype, is of special interest
because repetitive karyotyping showed the number of
affected metaphases to be gradually reduced during
lenalidomide treatment. Patient 2, who also had del(5q)
with a complex karyotype, experienced both complete
cytogenetic response and normalization of hemoglobin.
Two other patients with complex cytogenetic abnormalities
are being treated at our institution, but the duration of
treatment is too short for final evaluation.
Whereas cytogenetic remission with lenalidomide treat-
ment correlates closely with erythroid response [10],
complete suppression of the malignant clone was not
required for transfusion independence in four of the five
cases (patients 1, 3, 4, and 5) reported here. Hematologic
remissions occurred in three patients despite treatment
interruption and persistence of the del(5q) karyotype
(patients 3, 4, and 5). Patient 5 had a late effect and
reached transfusion independence after discontinuation of
lenalidomide. The long-term hematologic responses seen
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patient at our department had worsening of anemia 3 months
after stopping lenalidomide after a short period of admin-
istration (5 weeks).
Two other patients at our institution had interrupted
lenalidomide treatment after prolonged intake (at months 24
and 13, respectively) in complete hematologic and cytoge-
netic remission for reasons other than an adverse event.
Both patients remain in complete hematologic remission,
ongoing for more than 6 and 21 months. Thus, altogether
six out of 43 patients at our site have interrupted
lenalidomide treatment for non-toxicity reasons. Five
experienced an ongoing erythroid response and one patient
relapsed after 3 months.
Although all of the patients reported here have achieved
transfusion independence, lenalidomide treatment does not
uniformly lead to transfusion independence in del(5q)
MDS. Of note, the lenalidomide MDS 003 study in del
(5q) MDS patients shows that recurrence of the cytogenetic
aberration or cytogenetic evolution is not an uncommon
feature in this patient population during lenalidomide
treatment: New chromosomal abnormalities occurred in 24
out of 119 patients, and no single type was seen in more
than one patient [10]. Interestingly, chromosome 7 abnor-
malities occurred in only one patient, in contrast with the
higher incidence in the MDS 001 study [11].
List et al. suggested that lenalidomide may act by
suppression of the del(5q) clone [11]. All but one patient
in our series reported here had reduction of affected
metaphases, which supports this hypothesis. However, this
may not be a result of an immediate cytotoxic effect, as
evidenced by the slow decrease in malignant metaphases as
seen with patient 1. The other responding patients,
particularly patient 5, showed a slow erythroid response
more consistent with a sustained effect on the bone marrow
microenvironment. Effective bone marrow modulation
might, in some instances, lead to (partial) suppression of
del(5q) clones. However, even if clonal suppression did not
occur, normal hematopoiesis may be sufficiently strength-
ened to support a partial erythroid response in some
patients.
Examples of such erythroid response without alteration
of the underlying cytogenetic abnormality have occurred in
studies with other immunomodulating drugs like antithy-
mocyte globulin and cyclosporine A [15], differentiation-
inducing agents like all-trans-retinoic acid [8], and with
cytokine treatment like darbepoietin [13]. Thus, among
individual patients within the del(5q) MDS subset, lenali-
domide may affect the del(5q) clone and the bone marrow
microenvironment to different degrees to result in hemato-
poietic normalization. Further study is needed to better
understand the relationship between erythroid response and
cytogenetic remission with lenalidomide treatment.
In conclusion, although the above case reports obviously
represent only selected cases out of a larger number of
lenalidomide treated del(5q) MDS patients, these unusual
and unexpected cytogenetic and erythroid responses sug-
gest that some patients with complex karyotypes including
del(5q) or who discontinue therapy may still benefit from
lenalidomide treatment.
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